The Marshall Protocol Study Site Home

Search
   
Members

Calendar

Help

Home
Search by username
   Not logged in - Login | Register 


Mylan announces its Generic Olmesartan Medoxomil
 Moderated by: Prof Trevor Marshall
Topic closed

New Topic

Print
AuthorPost
Prof Trevor Marshall
Foundation Staff


Joined: Fri Jul 9th, 2004
Location: Thousand Oaks, California USA
Posts: 15481
Status:  Offline
 Posted: Wed Oct 26th, 2016 22:48
October 26 is the date upon which the US patent on Olmesartan Medoxomil ran out, and Mylan today announced their Generic version of Sankyo's Benicar.

http://newsroom.mylan.com/2016-10-26-Mylan-Launches-First-Generics-of-Benicar-and-Benicar-HCT-Tablets

There is a period of exclusivity given to Mylan before other manufacturers will be able to enter the market. It typically is 6 months.

In 2013, sales of Olmesartan Medoxomil generated 3 billion dollars worldwide in revenue for Dai-ichi Sankyo.

..Trevor..

NB: Please place discussion on this topic in the main discussion area of the forum at: https://www.marshallprotocol.com/view_topic.php?id=16661&forum_id=43

Prof Trevor Marshall
Foundation Staff


Joined: Fri Jul 9th, 2004
Location: Thousand Oaks, California USA
Posts: 15481
Status:  Offline
 Posted: Thu Oct 27th, 2016 11:27
Now Sankyo's Indian subsidiary announces it will have exclusive rights over Mylan. One billion dollars is a lot of money, folks...

http://money.livemint.com/news/company/news/sun-pharma%22s-arm-launches-ag-version-of-benicar-benicar-hct-azor-and-tribenzor-in-us-502307.aspx


 Current time is 04:43



* We can help you understand chronic disease, but only your physician is licensed to give you medical care *

Powered by WowBB 1.7 - Entire site Copyright © 2004-2018 Autoimmunity Research Foundation, All Rights Reserved
Click here to view our PRIVACY POLICY
Page processed in 0.0762 seconds (50% database + 50% PHP). 17 queries executed.